ArticleJournal of leukocyte biology2026
Circulating platelet-natural killer cell complexes are elevated in people living with human immunodeficiency virus on antiretroviral therapy.
Article in Journal of leukocyte biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Natural killer (NK) cells stand as a critical pillar in the innate immune defense against viral infections, particularly human immunodeficiency virus (HIV). However, during HIV infection, NK cells demonstrate profound dysfunction, undermining effective immune control and accelerating disease progression along with viral persistence. Understanding the mechanisms driving NK cell dysfunction is essential for the development of innovative therapeutic strategies. This study reveals a significant increase in circulating platelet-NK cell complexes (PNKCs) in individuals living with HIV (PWH) on antiretroviral therapy (ART) compared to those without HIV. PWH exhibited distinct NK cell phenotypes within PNKCs, characterized by elevated levels of CD25, interferon-gamma (IFN-γ), and natural killer group 2, member D (NKG2D), alongside decreased NKp46, relative to NK cells not engaged in complexes with platelets (non-PNKCs). Moreover, the sustained presence of platelets, or PNKCs, during in vitro NK cell expansion resulted in a heightened population of NK cells exhibiting an activated phenotype. In simian immunodeficiency virus-infected Rhesus macaques, PNKC levels were positively correlated with both plasma and cerebrospinal fluid viral loads, underscoring the role of PNKCs in disease progression. Notably, this correlation diminished following monoclonal antibody treatment with inclacumab, which inhibits P-selectin-dependent platelet interactions. We propose that the chronic activation of platelets during HIV infection fosters platelet interactions with NK cells in PWH on ART, ultimately contributing to NK cell dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.